Moos, Rita

Prion protein and Aβ‐related synaptic toxicity impairment

Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M., & Aguzzi, A. (2010) · EMBO Molecular Medicine

Alzheimer's disease research and treatmentsPrion Diseases and Protein Misfolding

Cited by 242

Engulfment of cerebral apoptotic bodies controls the course of prion disease in a mouse strain–dependent manner

Kranich, J., Krautler, N. J., Falsig, J., Ballmer, B., Li, S., Hutter, G., Schwarz, P., Moos, R., Julius, C., Miele, G., et al. (2010) · Journal of Experimental Medicine

Prion Diseases and Protein MisfoldingNeuroinflammation and Neurodegeneration Mechanisms

Cited by 110

Triggering receptor expressed on myeloid cells-2 is involved in prion-induced microglial activation but does not contribute to prion pathogenesis in mouse brains

Zhu, C., Herrmann, U. S., Li, B., Abakumova, I., Moos, R., Schwarz, P., Rushing, E. J., Colonna, M., & Aguzzi, A. (2015) · Neurobiology of Aging

Prion Diseases and Protein MisfoldingNeuroinflammation and Neurodegeneration Mechanisms

Cited by 44

Glial activation in prion diseases is selectively triggered by neuronal PrPSc

Lakkaraju, A. K. K., Sorce, S., Senatore, A., Nuvolone, M., Guo, J., Schwarz, P., Moos, R., Pelczar, P., & Aguzzi, A. (2022) · Brain Pathology

Prion Diseases and Protein MisfoldingNeuroinflammation and Neurodegeneration Mechanisms

Cited by 34

Cystatin F is a biomarker of prion pathogenesis in mice

Nuvolone, M., Schmid, N., Miele, G., Sorce, S., Moos, R., Schori, C., Beerli, R. R., Bauer, M., Saudan, P., Dietmeier, K., et al. (2017) · PLOS ONE

Prion Diseases and Protein MisfoldingAlzheimer's disease research and treatments

Cited by 25

Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling

Nuvolone, M., Paolucci, M., Sorce, S., Kana, V., Moos, R., Matozaki, T., & Aguzzi, A. (2017) · PLOS ONE

Prion Diseases and Protein MisfoldingNeuroinflammation and Neurodegeneration Mechanisms

Cited by 13